Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-28T14:20:53.341Z Has data issue: false hasContentIssue false

2.21 - Amantadine

from Medications for Motor/Neurologic Adverse Effects

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Typical or first-generation antipsychotic (FGA)

Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 200 - 203
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blanchet, P. J., Metman, L. V., Chase, T. N. (2003). Renaissance of amantadine in the treatment of Parkinson’s disease. Adv Neurol, 91, 251–257.Google ScholarPubMed
da Silva-Junior, F. P., Braga-Neto, P., Sueli Monte, F., et al. (2005). Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord, 11, 449–452.CrossRefGoogle ScholarPubMed
Citrome, L. (2016). Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next? CNS Spectr, 21, 1–12.CrossRefGoogle Scholar
Duwe, S. (2017). Influenza viruses – antiviral therapy and resistance. GMS Infect Dis, 5, Doc04.Google ScholarPubMed
Yang, T. T., Wang, L., Deng, X. Y., et al. (2017). Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci, 380, 256–261.CrossRefGoogle ScholarPubMed
Zheng, W., Wang, S., Ungvari, G. S., et al. (2017). Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol, 37, 341–346.CrossRefGoogle ScholarPubMed
Elkurd, M. T., Bahroo, L. B., Pahwa, R. (2018). The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag, 8, 73–80.Google Scholar
Hirjak, D., Kubera, K. M., Bienentreu, S., et al. (2019). Antipsychotic-induced motor symptoms in schizophrenic psychoses – Part 1: dystonia, akathisia und parkinsonism. Nervenarzt, 90, 1–11.CrossRefGoogle ScholarPubMed
Deleu, D., Northway, M. G., Hanssens, Y. (2002). Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet, 41, 261–309.CrossRefGoogle ScholarPubMed
Musharrafieh, R., Ma, C., Wang, J. (2020). Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31 N/L26I and M2-S31 N/V27A from the influenza A viruses. Eur J Pharm Sci, 141, 105124.CrossRefGoogle Scholar
PubChem. (2020). Amantadine, CID = 2130. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/amantadine (last accessed November 27, 2020).Google Scholar
Paik, J., Keam, S. J. (2018). Amantadine extended-release (GOCOVRI): a review in levodopa-induced dyskinesia in Parkinson’s disease. CNS Drugs, 32, 797–806.CrossRefGoogle ScholarPubMed
Mazzucchi, S., Frosini, D., Bonuccelli, U., et al. (2015). Current treatment and future prospects of dopa-induced dyskinesias. Drugs Today (Barc), 51, 315–329.CrossRefGoogle ScholarPubMed
Lin, C. C., Ondo, W. G. (2018). Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. J Neurol Sci, 389, 48–54.Google Scholar
Pahwa, R., Tanner, C. M., Hauser, R. A., et al. (2015). Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord, 30, 788–795.CrossRefGoogle ScholarPubMed
Faulkner, M. A. (2014). Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opin Drug Saf, 13, 1055–1069.CrossRefGoogle ScholarPubMed
Dubaz, O. M., Wu, S., Cubillos, F., et al. (2019). Changes in prescribing practices of dopaminergic medications in individuals with Parkinson’s disease by expert care centers from 2010 to 2017: The Parkinson’s Foundation Quality Improvement Initiative. Mov Disord Clin Pract, 6, 687–692.CrossRefGoogle ScholarPubMed
Aoki, F. Y., Sitar, D. S. (1988). Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet, 14, 35–51.CrossRefGoogle ScholarPubMed
Perez-Lloret, S., Rascol, O. (2018). Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna), 125, 1237–1250.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Amantadine
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Amantadine
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Amantadine
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×